MeSH term
Frequency | Condition_Probility | Adult | 21 | 0.0 |
Base Sequence | 8 | 0.0 |
DNA Primers | 4 | 0.0 |
Female | 32 | 0.0 |
Genotype | 11 | 0.0 |
Humans | 56 | 0.0 |
Male | 30 | 0.0 |
Middle Aged | 23 | 0.0 |
Phenotype | 4 | 0.0 |
Polymerase Chain Reaction | 7 | 0.0 |
*Polymorphism, Genetic | 5 | 0.0 |
Research Support, Non-U.S. Gov't | 35 | 0.0 |
*Genetic Predisposition to Disease | 5 | 0.0 |
Molecular Sequence Data | 4 | 0.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Sex Factors | 2 | 0.0 |
Transforming Growth Factor beta/*genetics/metabolism | 2 | 11.0 |
In Situ Hybridization | 4 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 12 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
Cell Line | 4 | 0.0 |
Adolescent | 8 | 0.0 |
Child | 6 | 0.0 |
Receptors, Transforming Growth Factor beta/*genetics | 2 | 4.0 |
Age Factors | 2 | 0.0 |
Aged | 14 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Cells, Cultured | 7 | 0.0 |
Child, Preschool | 4 | 0.0 |
Comparative Study | 8 | 0.0 |
Chromosomes, Human, Pair 19/*genetics | 3 | 3.0 |
Gene Frequency/genetics | 2 | 0.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 6 | 0.0 |
*Extracellular Matrix Proteins | 2 | 1.0 |
*Transforming Growth Factor beta | 2 | 1.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Interleukin-10/genetics | 2 | 4.0 |
Odds Ratio | 2 | 0.0 |
Polymorphism, Genetic | 6 | 0.0 |
Transforming Growth Factor beta/*genetics | 11 | 13.0 |
Cell Division | 5 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Gene Expression | 2 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
Haplotypes | 4 | 0.0 |
Microsatellite Repeats | 4 | 0.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Risk Assessment | 2 | 0.0 |
Alleles | 5 | 0.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Transforming Growth Factor beta/biosynthesis | 3 | 6.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 2 | 0.0 |
DNA Mutational Analysis | 3 | 0.0 |
Diaphyseal Dysplasia, Progressive/*genetics | 3 | 100.0 |
Case-Control Studies | 6 | 0.0 |
Chromosomes, Human, Pair 19 | 3 | 1.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Exons | 3 | 0.0 |
Introns | 3 | 0.0 |
Point Mutation | 2 | 0.0 |
Animals | 7 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Mice | 5 | 0.0 |
Genetic Markers | 5 | 0.0 |
Pedigree | 3 | 0.0 |
Transforming Growth Factor beta/genetics | 5 | 5.0 |
English Abstract | 4 | 0.0 |
Polymorphism, Genetic/*genetics | 3 | 0.0 |
Risk Factors | 3 | 0.0 |
Codon/*genetics | 2 | 3.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Infant | 3 | 0.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Age Distribution | 2 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Immunoglobulin E/blood | 2 | 1.0 |
In Vitro | 2 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Crosses, Genetic | 2 | 0.0 |
Transforming Growth Factor beta/pharmacology | 2 | 0.0 |
Gene Expression/drug effects | 2 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
*Gene Expression Profiling | 2 | 0.0 |
Proteins/genetics | 2 | 0.0 |
Gene Frequency | 2 | 0.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Trans-Activators/genetics | 2 | 0.0 |
